Jalali Seyed Amir, Parmiani Giorgio
Unit of Immuno-Biotherapy of Melanoma and Solid Tumors, Division of Molecular Oncology, San Raffaele Scientific Institute, Milan, Italy.
Recent Pat Biotechnol. 2011 Aug;5(2):108-17. doi: 10.2174/187220811796365716.
Peptides deriving from tumor-associated antigens and recognized by patient T cells have been firstly defined in the early 90's, and then used as vaccine in animal models and in cancer patients. Early trials showed a variable, often even high frequency of patients developing peptide-specific T-cell mediated immune response usually accompanied by a lower frequency of clinical response. Modified, long peptides could be synthesized with a higher in vitro binding to the corresponding HLA allele that only seldom translated into a clear improvement in the tumor response. However, we show here that more recent studies of multipeptide-based vaccines resulted in a higher and more robust T cell response causing also a more effective clinical response particularly in melanoma and prostate cancer patients. In this article, we also used some of the recent patents describing different inventions related to pre-clinical and clinical aspects of peptide based vaccines against human solid tumors.
源自肿瘤相关抗原且能被患者T细胞识别的肽段最早在90年代初被定义，随后被用作动物模型和癌症患者的疫苗。早期试验显示，患者产生肽特异性T细胞介导的免疫反应的频率各不相同，通常甚至很高，而临床反应的频率则较低。经过修饰的长肽可以合成，其与相应HLA等位基因的体外结合率更高，但很少能转化为肿瘤反应的明显改善。然而，我们在此表明，最近对基于多种肽的疫苗的研究产生了更高、更强健的T细胞反应，也导致了更有效的临床反应，特别是在黑色素瘤和前列腺癌患者中。在本文中，我们还使用了一些近期专利，这些专利描述了与针对人类实体瘤的基于肽的疫苗的临床前和临床方面相关的不同发明。
